Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.62 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.62 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.62 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167488 | 0.97 | KRAS (0.63) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL30167438 | 0.93 | KRAS (0.61) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23092305 | 0.91 | KRAS (0.67) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23093090 | 0.88 | KRAS (0.69) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23105132 | 0.88 | KRAS (0.70) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23092291 | 0.85 | KRAS (0.69) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23105193 | 0.85 | KRAS (0.64) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL24851170 | 0.83 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23092309 | 0.83 | KRAS (0.54) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636979 | 0.82 | KRAS (0.78) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | KRAS 1/4885EGFR 479/4885HMOX2 2652/4885 |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | KRAS 1/4885EGFR 246/4885HMOX2 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.